secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001654954-23-002947
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica reports 2022 revenue of $18.9M, up 361% YoY; net loss narrows to $17.0M
--------------------------------------------------------------------------------

- Revenue $18.9M, up 361% from $4.1M in 2021; 72% gross margin.
- Net loss $17.0M vs $18.4M in 2021; improvement of $1.4M (8%).
- Cash, equivalents and securities $156M at Dec 31, 2022; no SVB/Signature exposure.
- PulseVet small-animal device sales grew 405% in 2022; VetGuardian launched; TRUVIEW expected Q2 2023.
- Acquisitions of Assisi and Revo Squared contributed; evaluating further M&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423002947/0001654954-23-002947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423002947/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-002947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer